Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan in MPS IV A and VI
NCT03632213Phase 2Unknown
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Nov 2018
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mucopolysaccharidosis type IV A and mucopolysaccharidosis type VI comparing Losartan with Placebo (2 arms). Primary endpoint: Adverse events related to losartan use at 12 months. Status: unknown.
02
Drugs
losartan
03
Conditions
Mucopolysaccharidosis type IV Amucopolysaccharidosis type VI
Beyond the preview
Go deeper on NCT03632213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632213.